Navigation Links
Novavax CEO to Present at BIO Investor Forum 2008
Date:10/28/2008

ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the BIO Investor Forum 2008 at 8:30 am. (PT) on October 30, 2008 at the Palace Hotel in San Francisco, California. Dr. Singhvi will provide an overview of the company's strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
2. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
3. Novavax Announces Closing of $18 Million Registered Direct Offering
4. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
5. Novavax to Join Russell 3000 Index
6. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
7. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax Reports First Quarter 2008 Financial Results
10. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
11. Novavax Opens Its First U.S. Vaccine Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... The next time you are stung by a ... venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs ... or diagnose cancer. This research, described in the August ... ( http://www.fasebj.org ), shows how modified melittin may revolutionize ...
... by which Helicobacter pylori , the only known cancer-causing ... The new study, in the journal Oncogene , reports ... pylori infection and stomach cancer, the second leading cause ... population is infected with H. pylori, a bacterium that can ...
... genomes that potentially hide a rich array of pharmaceutical ... antibiotic. The study, reported in the August issue of ... serious diseases that are rapidly acquiring multi-drug resistance. ... successfully used a ,genome mining, approach to find and ...
Cached Biology News:Cancer-causing bacterium targets tumor-suppressor protein 2Cancer-causing bacterium targets tumor-suppressor protein 3Mining bacterial genomes reveals valuable 'hidden' drugs 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: